Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.
You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings
Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We’re driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.
In view of our vision of a world free of pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.
We follow a holistic and solution-agnostic approach to deliver highly effective pain treatments, building our programmes on a firm foundation of human pathophysiology and solid human target validation.
Ambition is welcome at Grünenthal. Whether you’re a world-class scientist or a talented graduate, together we drive cutting-edge research projects and develop products of the future. Grünenthal offers a culture of opportunity. Join us!
Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.
Aachen, 19th November 2015. Steffen Fritzsche (51) has been Head of Corporate Communications at Grünenthal since 1st November 2015. In this position he supports the Corporate Executive Board in internal and external communications regarding all matters of corporate interest. He succeeds Friederike Herrfurth, who left the company at her own request.
Aachen, Germany, November 17, 2015. Grünenthal announced today the exclusive license agreement with Depomed, Inc. (DEPO), a California based specialty pharmaceutical company commercializing products for pain and neurology, on the development and commercialization of Cebranopadol for the U.S. and Canada. Cebranopadol is a novel, first in class, potent analgesic for chronic pain which has demonstrated its efficacy in multiple Phase II trials in moderate to severe chronic pain.
Aachen, Germany, Copenhagen, Denmark, and Harlow, UK October 21, 2015 – Grünenthal GmbH, Nordic Bioscience A/S and Argenta Discovery 2009 Ltd., a Charles River company, announced today a collaboration to improve the research and development of therapeutic approaches in multi-organ fibrosis. With a particular focus on fast-progressing patient subpopulations, the collaboration aims to develop new and improved preclinical and clinical assays to optimize the identification of new therapies.
Quito, Ecuador and Aachen, Germany. October 1, 2015. The Grünenthal Group announces that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil, ANVISA (Agência Nacional de Vigilância Sanitária, Brazilian Health Surveillance Agency). This will allow Tecnandina to export pharmaceutical products also to Brazil and makes it the first production plant in Ecuador to receive ANVISA certification.
Aachen, Germany, September 22, 2015. The Grünenthal Group, a family owned international research based pharmaceutical company with headquarters in Germany, today announced that it has received EU marketing authorization for Zalviso® 15 micrograms sublingual tablets for the management of acute moderate to severe post-operative pain in adult patients. With the approval of the Zalviso® 15 micrograms sublingual tablets delivered through the easy-to-use, pre-programmed, non-invasive administration device, Grünenthal will enter the European hospital market and further build its leading position in the area of pain therapy innovation.
Vienna, September 3rd 2015. On occasion of the 9th Congress of the European Pain Federation EFIC®, young scientists from across Europe presented the latest results of their pain research projects, focussing on novel ideas with potential for achieving major advances in pain management. All presenters were former EFIC-GRÜNENTHAL Grant (E-G-G) winners, a grant which aims to support up-and-coming pain scientists.
Aachen, July 24, 2015 – The Grünenthal Group announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorization of sufentanil sublingual tablets for the management of acute moderate to severe post-operative pain in adult patients.
Aachen, Germany/Santiago de Chile, Chile/Boston, USA. June 12, 2015. Grünenthal Group, an international, family-owned pharmaceutical company, Proteus S.A. and Boston Children’s Hospital today announce a collaboration for neosaxitoxin, a novel anesthetic for local anesthesia and post-operative pain management. Following the respective agreement, both Proteus S.A. and Boston Children’s Hospital will remain as key members of the collaboration steering committee. The deal includes up to 85 million USD in upfront and development milestones plus undisclosed sales milestones and royalties.
Brussels/Aachen, June 12th, 2015. Pain is a common condition, which affects one in five adult citizens in Europe. They have persistent or chronic pain, a condition which affects the everyday lives of millions of people worldwide and which also poses a huge economic burden. Since 2004 the European Pain Federation EFIC® has cooperated with the pharmaceutical company Grünenthal GmbH, to support up-and-coming pain scientists in translating their experimental project ideas into funded pain research projects.
Brussels, February 24th, 2015 – One out of five Europeans is affected by chronic pain each year.1 But in 80 percent of cases physicians over- or underestimate the level of pain-related impairment of their patients.2 Therefore, it is crucial that patients are able to describe their symptoms as detailed as possible to their doctor to allow early diagnosis and increase chances of effective pain relief – an insight which has motivated Grünenthal to develop its “My pain feels like…” patient initiative, aiming at facilitating communication between patients and physicians.
Aachen, Germany, January 15, 2015. Grünenthal GmbH granted its consent with Janssen Pharmaceuticals Inc.’s (JPI) divestment of the license rights for Nucynta® (tapentadol), Nucynta® ER (tapentadol) extended-release tablets and Nucynta® (tapentadol) oral solution in the U.S. territory to Depomed, Inc. (DEPO), the company announced today.